Preeclampsia is a serious condition characterized by high blood pressure and organ damage in pregnancy, posing significant risks to both mothers and babies. Despite advances in maternal-fetal medicine, its prevention and early identification remain critical areas of focus. The US Preventive Services Task Force (USPSTF) guidelines recommend the use of low-dose aspirin in pregnancies deemed at risk, based on a defined set of clinical and demographic factors. However, a recent large-scale study has raised questions about the effectiveness and specificity of these guidelines.
Scientific and Clinical Evidence: What the Data Tell Us
A prospective cohort study, published in JAMA Network Open, investigated the clinical utility of the USPSTF guidelines. Conducted from July 2020 to March 2023, the study involved 5684 individuals with singleton pregnancies across 11 diverse medical centers in the United States. Participants were categorized into low-, moderate-, and high-risk groups based on USPSTF criteria. The results showed that an overwhelming 88.8% of the cohort was classified as at increased risk for preeclampsia, with 70.3% in the moderate-risk category and 18.5% in the high-risk category. However, actual preeclampsia diagnosis occurred in only 12.1% of the study population, including 23.5% of those in the high-risk group and 10.5% in the moderate-risk group. These findings raise concerns about the specificity of the guidelines.
Misconceptions and Harmful Behaviors
The study revealed discrepancies in the application of aspirin prophylaxis. While 82.0% of high-risk patients were recommended low-dose aspirin, only 50.4% of those with two or more moderate-risk factors received similar recommendations. Furthermore, adherence to aspirin use was notably low, with compliance rates under 25% among moderate-risk individuals. Such gaps may stem from physicians’ reluctance to prescribe aspirin broadly and from patient noncompliance, highlighting a need for better communication and education around the benefits of preventive measures.
Correct Health Practices and Practical Recommendations
One critical takeaway is the need to refine risk stratification tools. The study authors emphasize that moderate risk factors, when evaluated independently, offer limited predictive value. For instance, nulliparity (first-time pregnancy) was the only moderate risk factor consistently associated with a modest increase in preeclampsia risk. Other indicators, such as obesity and advanced maternal age, showed minimal or no predictive value in isolation. This suggests that a more holistic approach, integrating multiple risk factors within a diverse population, could enhance the accuracy of preeclampsia risk assessments.
Expert Insights and Commentary
Dr. Thomas McElrath, the study’s lead author, pointed out that labeling the majority of pregnant individuals as “at risk” undermines the guidelines’ purpose of targeting those who most need intervention. He advocates for the collective evaluation of risk factors to ensure clinical resources are effectively allocated. Similarly, Kara Boeldt, a preeclampsia survivor and advocate, highlighted the urgency of developing more precise predictive tools, given the condition’s potential severity. Innovations such as cell-free RNA blood tests, currently under development by researchers at Mirvie, represent promising steps towards personalized preeclampsia risk assessments.
Conclusion
The findings underscore the limitations of the current USPSTF guidelines in effectively identifying high-risk pregnancies for preeclampsia. By advancing research and adopting a more individualized approach to risk assessment, healthcare providers can enhance preventive strategies and ultimately improve maternal and neonatal outcomes. The study calls for a reevaluation of existing protocols to better serve pregnant individuals and address the growing challenge of preeclampsia.
References
– McElrath TF, Arun Jeyabalan, Arkady Khodursky, et al. Utility of the US Preventive Services Task Force for Preeclampsia Risk Assessment and Aspirin Prophylaxis. JAMA Network Open. 2025;8(7):e2521792-e2521792. doi:https://doi.org/10.1001/jamanetworkopen.2025.21792 – Mirvie. New study in JAMA Network Open shows current approaches to assessing preeclampsia risk are failing the majority of pregnant moms. EurekAlert. July 17, 2025. Accessed July 22, 2025. https://www.eurekalert.org/news-releases/1091599
– Mass General Brigham. Research Spotlight: evaluating the effectiveness of guidelines to predict the risk of preeclampsia. EurekAlert. July 17, 2025. Accessed July 22, 2025. https://www.eurekalert.org/news-releases/1091601